{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007961","form_type":"8-K","ticker":"HSDT","cik":"0001610853","company_name":"Solana Co","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.248674+00:00","generated_at":"2026-06-02T02:21:50.084890+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Helius Medical Q1 rev $135K (+22% YoY); net loss flat $2.5M; CMS PoNS reimbursement milestone","bullets":["Q1 revenue $135K vs $111K YoY; operating loss $3.4M vs $3.8M, driven by lower professional fees and clinical trial costs.","Net loss $2.5M (both periods); EPS -$3.08 vs -$4.42 in Q1 2023.","Cash $3.6M at March 31; raised $5.6M net in May public offering, extending cash runway into 2025.","Received CMS HCPCS preliminary reimbursement determination for PoNS; final price expected Oct 1, 2024.","Added six sites to stroke registrational program; reached FDA alignment on stroke development plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007961","json":"https://secwatch.observer/filing/0001558370-24-007961.json","markdown":"https://secwatch.observer/filing/0001558370-24-007961.md","text":"https://secwatch.observer/filing/0001558370-24-007961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610853/000155837024007961/0001558370-24-007961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610853/000155837024007961/hsdt-20240513x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:21:50.084890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c2899fccbed44e6ae97e29508be650ad4988ee5","claim":"Solana Co reported quarter ended March 31, 2024 results: revenue $135 thousand, net income net loss of $2.5 million, EPS $3.08 per share.","evidence_excerpt":"Services to make PoNS available to federal healthcare systems, including the U.S. Department of Veterans Affairs (“VA”) and Department of Defense (“DoD”). ​ ● Q1 2024 revenue of $135 thousand, compared to $111 thousand in Q1 2023, reflecting increased product sales in both the U.S. and Canada . ​ ● Closed on $6.4 million public offering, raising net proceeds of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610853/000155837024007961/0001558370-24-007961-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$135 thousand"},{"label":"Net income","value":"net loss of $2.5 million"},{"label":"EPS","value":"$3.08 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}